Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2004;35:147-150
Published online before print December 4, 2003, doi: 10.1161/01.STR.0000105396.93273.72
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
35/1/147    most recent
01.STR.0000105396.93273.72v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brown, D. L.
Right arrow Articles by Haley, E. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, D. L.
Right arrow Articles by Haley, E. C., Jr
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Stroke

(Stroke. 2004;35:147.)
© 2004 American Heart Association, Inc.


Original Contributions

Predicting Major Neurological Improvement With Intravenous Recombinant Tissue Plasminogen Activator Treatment of Stroke

Devin L. Brown, MD; Karen C. Johnston, MD, MSc; Douglas P. Wagner, PhD E. Clarke Haley, Jr, MD

From the Department of Neurology, University of Virginia Health System (D.L.B., K.C.J., E.C.H.), and Department of Health Evaluation Sciences, University of Virginia (K.C.J., D.P.W.), Charlottesville.

Correspondence to Devin L. Brown, MD, TC 1920/0316, 1500 E Medical Center Dr, Ann Arbor, MI 48109. E-mail devinb{at}umich.edu

Background and Purpose— In the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study, major neurological improvement within 24 hours (MNI) occurred significantly more frequently with recombinant tissue plasminogen activator (rtPA) treatment than with placebo. We explored the relationship between MNI and 3-month favorable outcome and sought clinical predictors of MNI.

Methods— Data from 312 rtPA-treated patients from the NINDS trial were used to assess the ability of MNI to predict favorable outcome at 3 months as defined by a modified Rankin Scale score of 0 to 1. Next, a multivariable predictive model was developed for MNI within the same data set. Clinical variables examined included age, time to treatment (TTT), diabetes, pretreatment glucose, baseline National Institutes of Health Stroke Scale score, pretreatment blood pressure, history of atrial fibrillation, weight >100 kg, and a dense artery sign. Finally, this model was used to forecast into the placebo group of the NINDS trial to assess the uniqueness of the predictors in the rtPA-treated group.

Results— MNI had a positive predictive value and negative predictive value of 0.70 for predicting favorable 3-month outcome. Only age [odds ratio (OR), 0.68; 95% confidence interval (CI), 0.47 to 0.99] and TTT (OR, 0.56; 95% CI, 0.34 to 0.91) appear to be independently associated with MNI. The model performed only moderately well (area under the receiver-operating characteristic curve, 0.66). Age (OR, 0.67; 95% CI, 0.45 to 0.99) but not TTT was associated with MNI in the placebo group.

Conclusions— MNI may be a useful surrogate for thrombolytic activity and is predictive of favorable 3-month outcome. When rates of MNI in different populations of stroke patients treated with thrombolysis are compared, adjustments for age and TTT may be necessary.


Key Words: forecasting • thrombolytic therapy • tissue plasminogen activator • treatment outcome




This article has been cited by other articles:


Home page
NeurologyHome page
S. Prabhakaran and M. S.V. Elkind
Vive la difference!: On potential sex differences in response to thrombolysis
Neurology, September 30, 2008; 71(14): 1048 - 1049.
[Full Text] [PDF]


Home page
StrokeHome page
W. S. Smith, G. Sung, J. Saver, R. Budzik, G. Duckwiler, D. S. Liebeskind, H. L. Lutsep, M. M. Rymer, R. T. Higashida, S. Starkman, et al.
Mechanical Thrombectomy for Acute Ischemic Stroke: Final Results of the Multi MERCI Trial
Stroke, April 1, 2008; 39(4): 1205 - 1212.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
R.I. Aviv, J. Mandelcorn, S. Chakraborty, D. Gladstone, S. Malham, G. Tomlinson, A.J. Fox, and S. Symons
Alberta Stroke Program Early CT Scoring of CT Perfusion in Early Stroke Visualization and Assessment
AJNR Am. J. Neuroradiol., November 1, 2007; 28(10): 1975 - 1980.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Mikulik, M. Ribo, M. D. Hill, J. C. Grotta, M. Malkoff, C. Molina, M. Rubiera, R. Delgado-Mederos, J. Alvarez-Sabin, A. V. Alexandrov, et al.
Accuracy of Serial National Institutes of Health Stroke Scale Scores to Identify Artery Status in Acute Ischemic Stroke
Circulation, May 22, 2007; 115(20): 2660 - 2665.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
M.S.V. Elkind, S. Prabhakaran, J. Pittman, W. Koroshetz, M. Jacoby, K. C. Johnston, and for the GAIN Americas Investigators
Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke
Neurology, March 13, 2007; 68(11): 842 - 848.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
O. Y. Bang, J. L. Saver, D. S. Liebeskind, S. Starkman, P. Villablanca, N. Salamon, B. Buck, L. Ali, L. Restrepo, F. Vinuela, et al.
Cholesterol level and symptomatic hemorrhagic transformation after ischemic stroke thrombolysis
Neurology, March 6, 2007; 68(10): 737 - 742.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
S. H. Shah, D. S. Liebeskind, J. L. Saver, S. Starkman, F. Vinuela, G. Duckwiler, R. Jahan, D. Kim, N. Sanossian, P. Vespa, et al.
Influence of gender on outcomes after intra-arterial thrombolysis for acute ischemic stroke
Neurology, June 13, 2006; 66(11): 1745 - 1746.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
A. Bruno, C. Saha, and L. S. Williams
Using Change in the National Institutes of Health Stroke Scale to Measure Treatment Effect in Acute Stroke Trials
Stroke, March 1, 2006; 37(3): 920 - 921.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
M. Yong, H.-C. Diener, M. Kaste, and J. Mau
Characteristics of Blood Pressure Profiles as Predictors of Long-Term Outcome After Acute Ischemic Stroke
Stroke, December 1, 2005; 36(12): 2619 - 2625.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
G. Saposnik, S. Di Legge, F. Webster, and V. Hachinski
Predictors of major neurologic improvement after thrombolysis in acute stroke
Neurology, October 25, 2005; 65(8): 1169 - 1174.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. Marti-Fabregas, M. Borrell, D. Cocho, R. Belvis, M. Castellanos, J. Montaner, J. Pagonabarraga, A. Aleu, L. Molina-Porcel, J. Diaz-Manera, et al.
Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA
Neurology, August 9, 2005; 65(3): 366 - 370.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
B. Ovbiagele and J. L. Saver
The smoking-thrombolysis paradox and acute ischemic stroke
Neurology, July 26, 2005; 65(2): 293 - 295.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
L. B. Goldstein and D. L. Simel
Is This Patient Having a Stroke?
JAMA, May 18, 2005; 293(19): 2391 - 2402.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
E. C. Haley Jr, P. D. Lyden, K. C. Johnston, T. M. Hemmen, and the TNK in Stroke Investigators
A Pilot Dose-Escalation Safety Study of Tenecteplase in Acute Ischemic Stroke
Stroke, March 1, 2005; 36(3): 607 - 612.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
G. Saposnik, B. Young, B. Silver, S. Di Legge, F. Webster, V. Beletsky, V. Jain, Y. Nilanont, and V. Hachinski
Lack of Improvement in Patients With Acute Stroke After Treatment With Thrombolytic Therapy: Predictors and Association With Outcome
JAMA, October 20, 2004; 292(15): 1839 - 1844.
[Abstract] [Full Text] [PDF]